Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/122308
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Soto, Marcelo | - |
dc.contributor.author | Sampietro-Colom, Laura | - |
dc.contributor.author | Lasalvia, Luis | - |
dc.contributor.author | Mira, Aurea | - |
dc.contributor.author | Jiménez Povedano, Wladimiro | - |
dc.contributor.author | Navasa, Miquel | - |
dc.date.accessioned | 2018-05-11T13:27:24Z | - |
dc.date.available | 2018-05-11T13:27:24Z | - |
dc.date.issued | 2017-05-07 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | http://hdl.handle.net/2445/122308 | - |
dc.description.abstract | AIM: To assess liver fibrosis (LF) in hepatitis C virus (HCV) and alcoholic liver disease (ALD), estimate health outcomes and costs of new noninvasive testing strategies. METHODS: A Markov model was developed to simulate LF progression in HCV and ALD for a cohort of 40-year-old men with abnormal levels of transaminases. Three different testing alternatives were studied: a single liver biopsy; annual Enhanced liver fibrosis (ELF ) followed by liver stiffness measurement (LSM) imaging as a confirmation test if the ELF test is positive; and annual ELF test without LSM. The analysis was performed from the perspective of a university hospital in Spain. Clinical data were obtained from published literature. Costs were sourced from administrative databases of the hospital. Deterministic and probabilistic sensitivity analyses were performed RESULTS: In HCV patients, annual sequential ELF test/LSM and annual ELF test alone prevented respectively 12.9 and 13.3 liver fibrosis-related deaths per 100 persons tested, compared to biopsy. The incremental cost-effectiveness ratios (ICERs) were respectively 13400 and 11500 per quality-adjusted life year (QALY). In ALD, fibrosis-related deaths decreased by 11.7 and 22.1 per 100 persons tested respectively with sequential ELF test/LSM and annual ELF test alone. ICERs were 280 and 190 per QALY, respectively. CONCLUSION: The use of the ELF test with or without a confirmation LSM are cost-effective options compared to a single liver biopsy for testing liver fibrosis in HCV and ALD patients in Spain. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Baishideng Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3748/wjg.v23.i17.3163 | - |
dc.relation.ispartof | World Journal of Gastroenterology, 2017, vol. 23, num. 17, p. 3163-3173 | - |
dc.relation.uri | https://doi.org/10.3748/wjg.v23.i17.3163 | - |
dc.rights | cc-by-nc (c) Soto, Marcelo et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Hepatitis C | - |
dc.subject.classification | Malalties del fetge | - |
dc.subject.other | Hepatitis C | - |
dc.subject.other | Liver diseases | - |
dc.title | Cost-effectiveness of nehanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 672060 | - |
dc.date.updated | 2018-05-11T13:27:24Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28533673 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Biomedicina) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
672060.pdf | 2.59 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License